Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
17 Cards in this Set
- Front
- Back
|
Indications for antiplatelet agent? (3) |
1. Large-vessel stenosis ( extracranial or intracranial) 2. Small-vessel disease or lacunar stroke 3. Cryptogenic stroke |
|
|
Indications for anticoagulation? (4) |
1. Atrial fibrillation 2. Mechanical heart valve 3. Left ventricular or left atrial thrombus 4. Cerebral venous thrombosis |
|
|
Which stroke patients or TIA patients shoulud be prescribed an antithrombotic? |
All patients |
|
|
Short-term use (<90 days) of acetylsalicylic acid in combination with clopidogrel? |
Not been shown to increase the risk of bleeding; however, long-term use is not generally recommended for secondary stroke prevention unless there is another indication, such as a drug-eluting carotid artery stent |
|
|
Common reasons for failure of antiplatelet therapy? (4) |
1. Non-adherence 2. Concomitant use of NSAIDs or COX-2 inhibitors with acetylsalicylic acid 3. Impaired metabolism of clopidogrel (concomitant use with PPIs or other medications; patient may be a genetically poor metabolizer) 4. Poor response (resistance) |
|
|
Treatment for atrial fibrillation? |
If no contraindications exist, patients with both TIA and AF should begin oral anticoagulation after CT or MRI of the brain has excluded intracranial hemorrhage or large infarct |
|
|
Choices of anticoagulation for AF and stroke/TIA? (4) |
1. Warfarin 2. Dabigatran 3. Rivaroxaban 4. Apixaban |
|
|
Single most important modifiable risk factor for stroke? |
Hypertension |
|
|
Blood pressure recommendations in the subacute phase of a stroke? |
<140/90 |
|
|
What constitutes high-intensity statin therapy? |
1. 40- to 80-mg doses of atorvastatin daily 2. 20- to 40-mg doses of rosuvastatin daily |
|
|
First trial to show a reduction in the recurrent risk of ischemic stroke in addition to a reduuction in myocardial infarction? |
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) |
|
|
What was the purpose of the SPARCL trial? |
First trial to show a reduction in the recurrent risk of ischemic stroke in addition to a reduuction in myocardial infarction? |
|
|
HbA1c target in patients with diabetes mellitus type 1 or 2 and stroke or TIA? |
Below 7% |
|
|
Ipsilateral risk of ischemic stroke in patients with a tenosis of more than 60%? |
2% to 3% annually |
|
|
In patients with asymptomatic internal carotid artery stenosis of more than 60%, how much will intervention reduce the risk to? |
1% annually |
|
|
Risk of intervention in asymptomatic ICA stenosis >60%? |
1.5% to 3% |
|
|
Emerging risk factor for stroke? |
Obstructive Sleep Apnea; treat with CPAP or weight loss and positioning to avoid back sleeping |
